## Sonia HernÃ;ndez-DÃ-az

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10923175/publications.pdf

Version: 2024-02-01

100 papers 14,082 citations

<sup>38720</sup>
50
h-index

99 g-index

102 all docs 102 docs citations

times ranked

102

13987 citing authors

#	Article	IF	Citations
1	Ischemic Placental Disease, Preterm Delivery, and Their Association With Opioid Use During Pregnancy. American Journal of Epidemiology, 2022, 191, 759-768.	1.6	6
2	Trajectories of Prescription Opioid Utilization During Pregnancy Among Prepregnancy Chronic Users and Risk of Neonatal Opioid Withdrawal Syndrome. American Journal of Epidemiology, 2022, 191, 208-219.	1.6	4
3	Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction. Human Reproduction, 2022, 37, 793-805.	0.4	8
4	Effectiveness and safety of intrauterine insemination vs. assisted reproductive technology: emulating a target trial using an observational database of administrative claims. Fertility and Sterility, 2022, 117, 981-991.	0.5	8
5	Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders. JAMA Internal Medicine, 2022, 182, 522.	2.6	22
6	International Registry of Coronavirus Exposure in Pregnancy (IRCEP) – Cohort Description and Methodological Considerations. American Journal of Epidemiology, 2022, , .	1.6	7
7	Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine. Cephalalgia, 2021, 41, 392-403.	1.8	8
8	Chronic prescription opioid use in pregnancy in the United States. Pharmacoepidemiology and Drug Safety, 2021, 30, 504-513.	0.9	7
9	Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study. BMJ, The, 2021, 372, n102.	3.0	26
10	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. Inflammatory Bowel Diseases, 2021, 27, 1427-1434.	0.9	6
11	Validity of claimsâ€based algorithms to identify neurodevelopmental disorders in children. Pharmacoepidemiology and Drug Safety, 2021, 30, 1635-1642.	0.9	14
12	Using nationally representative survey data for external adjustment of unmeasured confounders: An example using the NHANES data. Pharmacoepidemiology and Drug Safety, 2020, 29, 1151-1158.	0.9	4
13	Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Medicine, 2020, 17, e1003322.	3.9	27
14	In utero opioid exposure and risk of infections in childhood: A multinational Nordic cohort study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1596-1604.	0.9	4
15	The Effect of Prenatal Treatments on Offspring Events in the Presence of Competing Events. Epidemiology, 2020, 31, 636-643.	1.2	20
16	Quantification of selection bias in studies of risk factors for birth defects among livebirths. Paediatric and Perinatal Epidemiology, 2020, 34, 655-664.	0.8	27
17	Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ, The, 2020, 369, m1494.	3.0	17
18	Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ, The, 2020, 368, m237.	3.0	28

#	Article	IF	Citations
19	The Impact of Technology on the Diagnosis of Congenital Malformations. American Journal of Epidemiology, 2019, 188, 1892-1901.	1.6	5
20	Use of realâ€world evidence from healthcare utilization data to evaluate drug safety during pregnancy. Pharmacoepidemiology and Drug Safety, 2019, 28, 906-922.	0.9	79
21	Good practices for the design, analysis, and interpretation of observational studies on birth spacing and perinatal health outcomes. Paediatric and Perinatal Epidemiology, 2019, 33, O15-O24.	0.8	49
22	Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with threeâ€group matching weights. Pharmacoepidemiology and Drug Safety, 2018, 27, 182-190.	0.9	13
23	Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations. JAMA Psychiatry, 2018, 75, 167.	6.0	93
24	Prenatal Treatment and Outcomes of Women With Opioid Use Disorder. Obstetrics and Gynecology, 2018, 132, 916-922.	1.2	31
25	Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA - Journal of the American Medical Association, 2018, 320, 2429.	3.8	90
26	$\hat{l}^2$ -Blocker Use in Pregnancy and the Risk for Congenital Malformations. Annals of Internal Medicine, 2018, 169, 665.	2.0	65
27	Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials. Journal of Clinical Epidemiology, 2018, 103, 10-21.	2.4	30
28	Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. American Journal of Psychiatry, 2018, 175, 564-574.	4.0	61
29	Risk of Major Malformations in Infants Following First-Trimester Exposure to Quetiapine. American Journal of Psychiatry, 2018, 175, 1225-1231.	4.0	28
30	Lithium Use in Pregnancy and the Risk of Cardiac Malformations. New England Journal of Medicine, 2017, 376, 2245-2254.	13.9	183
31	Zidovudine use in pregnancy and congenital malformations. Aids, 2017, 31, 1733-1743.	1.0	12
32	Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. Obstetrics and Gynecology, 2017, 129, 174-184.	1.2	77
33	Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstetrics and Gynecology, 2017, 130, 1192-1201.	1.2	50
34	Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ: British Medical Journal, 2017, 358, j3326.	2.4	104
35	Late Pregnancy $\hat{I}^2$ Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. Pediatrics, 2016, 138, .	1.0	89
36	Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry, 2016, 73, 938.	6.0	206

#	Article	IF	Citations
37	Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. Journal of Clinical Epidemiology, 2016, 79, 70-75.	2.4	449
38	Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. American Journal of Psychiatry, 2016, 173, 263-270.	4.0	162
39	The Most Commonly Dispensed Prescription Medications Among Pregnant Women Enrolled in the U.S. Medicaid Program. Obstetrics and Gynecology, 2015, 126, 465-473.	1.2	104
40	Calcium Channel Blocker Exposure in Late Pregnancy and the Risk of Neonatal Seizures. Obstetrics and Gynecology, 2015, 126, 271-278.	1.2	15
41	Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. Pharmacoepidemiology and Drug Safety, 2015, 24, 934-942.	0.9	33
42	Beginning and duration of pregnancy in automated health care databases: review of estimation methods and validation results. Pharmacoepidemiology and Drug Safety, 2015, 24, 335-342.	0.9	56
43	Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn. JAMA - Journal of the American Medical Association, 2015, 313, 2142.	3.8	198
44	Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. JAMA Neurology, 2015, 72, 981.	4.5	201
45	Statins and congenital malformations: cohort study. BMJ, The, 2015, 350, h1035-h1035.	3.0	172
46	Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. BMJ, The, 2015, 350, h2102-h2102.	3.0	140
47	Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. American Journal of Obstetrics and Gynecology, 2015, 212, 337.e1-337.e14.	0.7	63
48	Antidepressant Use in Pregnancy and the Risk of Cardiac Defects. New England Journal of Medicine, 2014, 371, 1167-1169.	13.9	29
49	Validity of maternal and infant outcomes within nationwide Medicaid data. Pharmacoepidemiology and Drug Safety, 2014, 23, 646-655.	0.9	81
50	First Trimester Exposure to Antiretroviral Therapy and Risk of Birth Defects. Pediatric Infectious Disease Journal, 2014, 33, 741-746.	1.1	19
51	Increase in Prescription Opioid Use During Pregnancy Among Medicaid-Enrolled Women. Obstetrics and Gynecology, 2014, 123, 997-1002.	1.2	291
52	Invited Commentary: Composite Outcomes as an Attempt to Escape From Selection Bias and Related Paradoxes. American Journal of Epidemiology, 2014, 179, 368-370.	1.6	34
53	Alteration of bioelectrically-controlled processes in the embryo: a teratogenic mechanism for anticonvulsants. Reproductive Toxicology, 2014, 47, 111-114.	1.3	33
54	Antidepressant Use in Pregnancy and the Risk of Cardiac Defects. New England Journal of Medicine, 2014, 370, 2397-2407.	13.9	296

#	Article	IF	Citations
55	Patterns of Opioid Utilization in Pregnancy in a Large Cohort of Commercial Insurance Beneficiaries in the United States. Anesthesiology, 2014, 120, 1216-1224.	1.3	180
56	Reply. Obstetrics and Gynecology, 2014, 124, 638.	1.2	0
57	Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiology and Drug Safety, 2013, 22, 16-24.	0.9	154
58	Risk of Complications After a Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors. Digestive Diseases and Sciences, 2013, 58, 1653-1662.	1.1	10
59	Assessment of Antihistamine Use in Early Pregnancy and Birth Defects. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 666-674.e1.	2.0	32
60	Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ, The, 2013, 347, f4877-f4877.	3.0	94
61	National trends in antidepressant medication treatment among publicly insured pregnant women. General Hospital Psychiatry, 2013, 35, 265-271.	1.2	135
62	Nonsteroidal Antiinflammatory Drugs in Late Pregnancy and Persistent Pulmonary Hypertension of the Newborn. Pediatrics, 2013, 131, 79-87.	1.0	64
63	Use of Decongestants During Pregnancy and the Risk of Birth Defects. American Journal of Epidemiology, 2013, 178, 198-208.	1.6	59
64	Challenges of using primary care electronic medical records in the UK to study medications in pregnancy. Pharmacoepidemiology and Drug Safety, 2013, 22, 977-985.	0.9	24
65	Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiology and Drug Safety, 2013, 22, 1013-1018.	0.9	140
66	Randomized Trials Analyzed as Observational Studies. Annals of Internal Medicine, 2013, 159, 560-2.	2.0	125
67	Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations. PLoS ONE, 2013, 8, e67405.	1.1	140
68	Patterns of Outpatient Antihypertensive Medication Use During Pregnancy in a Medicaid Population. Hypertension, 2012, 60, 913-920.	1.3	48
69	Beyond the intention-to-treat in comparative effectiveness research. Clinical Trials, 2012, 9, 48-55.	0.7	348
70	Use of topiramate in pregnancy and risk of oral clefts. American Journal of Obstetrics and Gynecology, 2012, 207, 405.e1-405.e7.	0.7	130
71	Hypertension in Women of Reproductive Age in the United States: NHANES 1999-2008. PLoS ONE, 2012, 7, e36171.	1.1	104
72	Antibiotics and oral contraceptive failure â€" a case-crossover study. Contraception, 2011, 83, 418-425.	0.8	37

#	Article	IF	CITATIONS
73	Name of the Bias and Sex of the Angels. Epidemiology, 2011, 22, 232-233.	1.2	5
74	Is there a direct effect of preâ€eclampsia on cerebral palsy not through preterm birth?. Paediatric and Perinatal Epidemiology, 2011, 25, 111-115.	0.8	46
75	Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. American Journal of Obstetrics and Gynecology, 2011, 205, 51.e1-51.e8.	0.7	587
76	Estimating Absolute Risks in the Presence of Nonadherence. Epidemiology, 2010, 21, 528-539.	1.2	57
77	Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension. American Journal of Psychiatry, 2009, 166, 320-328.	4.0	89
78	Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatric and Perinatal Epidemiology, 2009, 23, 18-28.	0.8	70
79	Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction. Journal of Clinical Psychopharmacology, 2009, 29, 555-560.	0.7	70
80	From causal diagrams to birth weight-specific curves of infant mortality. European Journal of Epidemiology, 2008, 23, 163-166.	2.5	38
81	Positive predictive value of computerized records for major congenital malformations. Pharmacoepidemiology and Drug Safety, 2008, 17, 455-460.	0.9	51
82	Risk Factors for Persistent Pulmonary Hypertension of the Newborn. Pediatrics, 2007, 120, e272-e282.	1.0	163
83	Toh et al. Respond to "Compromise or Compromising?". American Journal of Epidemiology, 2007, 167, 644-645.	1.6	1
84	First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. New England Journal of Medicine, 2007, 356, 2675-2683.	13.9	467
85	Prescription of medications during pregnancy: accidents, compromises, and uncertainties. Pharmacoepidemiology and Drug Safety, 2006, 15, 613-617.	0.9	15
86	Can folic acid protect against congenital heart defects in down syndrome?. Birth Defects Research Part A: Clinical and Molecular Teratology, 2006, 76, 714-717.	1.6	10
87	Invited Commentary: Simple Models for a Complicated Reality. American Journal of Epidemiology, 2006, 164, 312-314.	1.6	8
88	The Birth Weight "Paradox" Uncovered?. American Journal of Epidemiology, 2006, 164, 1115-1120.	1.6	303
89	Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. New England Journal of Medicine, 2006, 354, 579-587.	13.9	821
90	Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors. New England Journal of Medicine, 2006, 354, 2443-2451.	13.9	1,100

#	Article	IF	CITATIONS
91	Use of over-the-counter medications during pregnancy. American Journal of Obstetrics and Gynecology, 2005, 193, 771-777.	0.7	331
92	Methylenetetrahydrofolate Reductase Polymorphisms and the Risk of Gestational Hypertension. Epidemiology, 2005, 16, 628-634.	1.2	16
93	A Structural Approach to Selection Bias. Epidemiology, 2004, 15, 615-625.	1.2	2,017
94	Case-Crossover and Case-Time-Control Designs in Birth Defects Epidemiology. American Journal of Epidemiology, 2003, 158, 385-391.	1.6	57
95	Causal Knowledge as a Prerequisite for Confounding Evaluation: An Application to Birth Defects Epidemiology. American Journal of Epidemiology, 2002, 155, 176-184.	1.6	1,107
96	Dietary Folate and the Risk of Nonfatal Myocardial Infarction. Epidemiology, 2002, 13, 700-706.	1.2	23
97	Risk of Gestational Hypertension in Relation to Folic Acid Supplementation during Pregnancy. American Journal of Epidemiology, 2002, 156, 806-812.	1.6	76
98	latrogenic legacy from diethylstilbestrol exposure. Lancet, The, 2002, 359, 1081-1082.	6.3	24
99	Incidence of serious upper gastrointestinal bleeding/perforation in the general population:. Journal of Clinical Epidemiology, 2002, 55, 157-163.	2.4	131
100	Folic Acid Antagonists during Pregnancy and the Risk of Birth Defects. New England Journal of Medicine, 2000, 343, 1608-1614.	13.9	689